Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
暂无分享,去创建一个
[1] M. Danhof,et al. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[2] Michael G. M. Derks,et al. Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. , 1999, Pulmonary pharmacology & therapeutics.
[3] N. Holford. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.
[4] H. Derendorf,et al. Mathematical modeling of cortisol circadian rhythm and cortisol suppression , 1996 .
[5] R. Mathôt,et al. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance , 1999, Clinical pharmacology and therapeutics.
[6] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[7] J. Barrett,et al. Population Pharmacokinetics and Pharmacodynamics of Ciclesonide , 2003, Journal of clinical pharmacology.
[8] E. R. Garrett,et al. Psicofuranine: kinetics and mechanisms in vivo with the application of the analog computer. , 1960, The Journal of pharmacology and experimental therapeutics.
[9] William J. Jusko,et al. Receptor-mediated pharmacodynamics of prednisolone in the rat , 1986, Journal of Pharmacokinetics and Biopharmaceutics.
[10] W J Jusko,et al. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. , 2000, The Journal of pharmacology and experimental therapeutics.
[11] D. Drayer,et al. Hydromorphone levels and pain control in patients with severe chronic pain , 1988, Clinical pharmacology and therapeutics.
[12] Hartmut Derendorf,et al. Pharmacokinetic/pharmacodynamic studies in drug product development. , 2002, Journal of pharmaceutical sciences.
[13] John Anthony Bauer,et al. Application of Pharmacodynamic Modeling for Designing Time-Variant Dosing Regimens to Overcome Nitroglycerin Tolerance in Experimental Heart Failure , 1997, Pharmaceutical Research.
[14] B. Lipworth. The problem of dose-response and therapeutic ratio of inhaled steroids. , 2001, American journal of respiratory and critical care medicine.
[15] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[16] M. Danhof,et al. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. , 1989, The Journal of pharmacology and experimental therapeutics.
[17] J. C. Matthews. Fundamentals of Receptor, Enzyme, and Transport Kinetics , 1993 .
[18] L. Sheiner,et al. Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.
[19] R. Koopmans,et al. Pharmacodynamic modelling of the drug-induced downregulation of a β2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone , 2004, European Journal of Clinical Pharmacology.
[20] M. Karlsson,et al. Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors , 1999 .
[21] K. Lasseter,et al. Population Pharmacokinetics and Pharmacodynamics of Pyridostigmine Bromide for Prophylaxis against Nerve Agents in Humans , 1998, Journal of clinical pharmacology.
[22] W. Colburn. Optimizing the Use of Biomarkers, Surrogate Endpoints, and Clinical Endpoints for More Efficient Drug Development , 2000, Journal of clinical pharmacology.
[23] Younggil Kwon,et al. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.
[24] M. Weir,et al. The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .
[25] J. Wagner,et al. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.
[26] H. Derendorf,et al. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. , 1997, International journal of clinical pharmacology and therapeutics.
[27] E. Zuhowski,et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] F. Brosstad,et al. Increased Potency and Decreased Elimination of Lamifiban, a GPIIb-IIIa Antagonist, in Patients with Severe Renal Dysfunction , 1998, Thrombosis and Haemostasis.
[29] W. Jusko,et al. Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10 , 1998, Pharmaceutical Research.
[30] B. Jensen,et al. Pharmacokinetics and Concentration‐Effect Analysis of Intravenous RGD891, a Platelet GPIIb/IIIa Antagonist, Using Mixed‐Effects Modeling (NONMEM) , 2000, Journal of clinical pharmacology.
[31] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[32] H Derendorf,et al. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. , 1997, International journal of clinical pharmacology and therapeutics.
[33] S L Shafer,et al. Pharmacokinetic‐pharmacodynamic modeling in drug development: Application to the investigational opioid trefentanil , 1994, Clinical pharmacology and therapy.
[34] G Levy,et al. Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.
[35] S. Khor,et al. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. , 2000, The Journal of pharmacology and experimental therapeutics.
[36] J. Chan,et al. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes , 2000, European Journal of Clinical Pharmacology.
[37] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[38] R. Heinig,et al. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form , 1997, European Journal of Clinical Pharmacology.
[39] S. Mousa,et al. Disposition and exposure of the fibrinogen receptor antagonist XV459 on αIIBβ3 binding sites in the guinea pig , 1999 .
[40] M. Gibaldi,et al. Pharmacokinetics, Second Edition , 1982 .
[41] S. de Jongh,et al. The influence of divided doses of drugs on the duration of effect and integral of effect. , 1950, Acta physiologica et pharmacologica Neerlandica.
[42] B. Jensen,et al. Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients , 2000, Journal of clinical pharmacology.
[43] J. Barrett,et al. PHARMACOKINETICS AND SAFETY OF A SELEGILINE TRANSDERMAL SYSTEM RELATIVE TO SINGLE‐DOSE ORAL ADMINISTRATION IN THE ELDERLY , 1996, American journal of therapeutics.
[44] P. Molinoff,et al. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. , 1989, Circulation.
[45] S. Waldman,et al. Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End‐Stage Renal Insufficiency , 2000, Journal of clinical pharmacology.
[46] D. Shand,et al. Plasma concentrations and the time‐course of beta blockade due to propranolol , 1975, Clinical pharmacology and therapeutics.
[47] T. Müller,et al. Inhibition of Platelet Aggregation as a Surrogate Marker , 1997, Journal of clinical pharmacology.
[48] L B Sheiner,et al. Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.
[49] Jogarao V. S. Gobburu,et al. Application of Resampling Techniques to Estimate Exact Significance Levels for Covariate Selection During Nonlinear Mixed Effects Model Building: Some Inferences , 2004, Pharmaceutical Research.
[50] L B Sheiner,et al. Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.
[51] Hartmut Derendorf,et al. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.
[52] Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development , 1992 .
[53] M. Weaver,et al. Pilocarpine Disposition and Salivary Flow Responses Following Intravenous Administration to Dogs , 1992, Pharmaceutical Research.
[54] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[55] J L Steimer,et al. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[56] C. Funck-Brentano,et al. Pharmacokinetic‐pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers , 1998, Clinical pharmacology and therapeutics.
[57] J. Barrett,et al. Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century , 2000, Journal of clinical pharmacology.
[58] H. Derendorf,et al. Handbook of Pharmacokinetic/Pharmacodynamic Correlation , 1995 .
[59] R. Straka,et al. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[60] R Bruno,et al. Pharmacokinetics/Pharmacodynamics in Drug Development: An Industrial Perspective , 2000, Journal of clinical pharmacology.
[61] P. Rolan,et al. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. , 1995, British journal of clinical pharmacology.
[62] H. Möllmann,et al. Pharmacokinetic/Pharmacodynamic Evaluation of Deflazacort in Comparison to Methylprednisolone and Prednisolone , 1995, Pharmaceutical Research.
[63] M. Bottorff,et al. Labetalol pharmacokinetics and pharmacodynamics: Evidence of stereoselective disposition , 1990, Clinical pharmacology and therapeutics.
[64] M. Danhof,et al. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.
[65] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[66] R. Jackson. A Pharmacokinetic–Pharmacodynamic Model of Chemotherapy of Human Immunodeficiency Virus Infection that Relates Development of Drug Resistance to Treatment Intensity , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[67] D. Shindler,et al. A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects , 1997, Journal of clinical pharmacology.
[68] M Kac,et al. Some mathematical models in science. , 1969, Science.
[69] Lewis B. Sheiner,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Pharmaceutical Research.
[70] N. Holford,et al. Perioperative Pharmacodynamics of Acetaminophen Analgesia in Children , 1999 .
[71] B. Jensen,et al. Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers , 2000, Journal of clinical pharmacology.
[72] W. Jusko,et al. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. , 1998, The Journal of pharmacology and experimental therapeutics.
[73] S. Tunn,et al. Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids , 1993, Journal of clinical pharmacology.